Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
GDRX.US
id: 967, Created by , Scout

GoodRx (GDRX) Retraction of fiscal Y2022 Guidance Case

  • In May 2022, GoodRx retracted its Y2022 guidance and announced negative revenue impact for Q2’22.
  • On it, $GDRX fell 25.9%, losing $256M+ of shareholder value.
  • Investors may have grounds to suspect GoodRx of having distribution problems.
On May 9, 2022, after the market closed, GoodRx announced its Q1’ 22 financial results and withdrew its fiscal 2022 guidance.
  • In shareholder letter, Company indicated pricing issues with a large distributor.
  • Also, Company expects negative revenue impact around $30M.
  • It further expects the matter to be ongoing without amelioration through Q2.
On this news, $GDRX fell 25.9% and lost over $256 million of its market capitalization, seriously damaging shareholders.

Considering all the information, investors might have grounds to suspect that GoodRx and its executives failed to timely disclose and resolve distribution issues, which consequently led to their losses.

The case is already under investigation by at least one of the reputable law firms.
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
10 May 2022
Collecting participants…

Goodrx Holdings Inc

GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company...

    Ticker
    GDRX.US
    ISIN
    US38246G1085
    CIK
    1809519
    Sector
    Healthcare
    Industry
    Health Information Services
    Country
    USA
    Address
    2701 Olympic Boulevard, Santa Monica, CA, United States, 90404